Eledon Pharmaceuticals Updates Mid-Stage Trial Data for Tegoprubart
Eledon Pharmaceuticals (NASDAQ:ELDN) reported updated long-term data from its Phase 2 BESTOW trial involving tegoprubart, the company's lead drug candidate. The update comes alongside an announcement that the U.S. Food and Drug Administration has granted Fast Track designation to tegoprubart for further development. The biotech firm noted positive developments in the ongoing clinical evaluation of tegoprubart, which is being studied as a potential treatment for certain neurological conditions. These updates contributed to increased investor interest, reflected by higher trading activity on Tuesday.
